Cavernous malformations, also known as "cavernous angiomas," "cavernous hemangiomas" or just "cavernomas" are clusters of tightly packed abnormal blood vessels surrounded by normal brain tissue.

Smith and the CSIC team's latest research focuses on understanding the genetic and pathological foundations of cerebral cavernous malformations (CCMs). Their work investigates specific ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...

Cerebral vascular malformations (CVMs), including cerebral arteriovenous malformations (AVMs) and cavernous malformations (CCMs), have long posed challenges due to their complex origins and severe ...

Recursion announced the results from its Phase 2 SYCAMORE trial of REC-994, a treatment for Cerebral Cavernous Malformations (CCM), at the International Stroke Conference. The trial met its ...